Search

Your search keyword '"Birch, Simone"' showing total 41 results
Start Over Author "Birch, Simone"
41 results on '"Birch, Simone"'

1. Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Author

Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Fennell, Éanna, Hennessy, Aoife, Leahy, Ciara I., Murray, Paul G., Bednarska, Karolina, Brosda, Sandra, Trotman, Judith, Berkahn, Leanne, Zaharia, Andreea, Birch, Simone, Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, and Nath, Karthik

Published
2024
Full Text
View/download PDF

2. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma

Author

Keane, Colm, Law, Soi C., Gould, Clare, Birch, Simone, Sabdia, Muhammed B., Merida de Long, Lilia, Thillaiyampalam, Gayathri, Abro, Emad, Tobin, Joshua W., Tan, Xiaohong, Xu-Monette, Zijun Y., Young, Ken H., Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Gill, Anthony, Talaulikar, Dipti, Jain, Sanjiv, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Cross, Donna, Hertzberg, Mark, and Gandhi, Maher K.

Published
2020
Full Text
View/download PDF

3. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Author

Barraclough, Allison, Alzahrani, Musa, Ettrup, Marianne Schmidt, Bishton, Mark, van Vliet, Chris, Farinha, Pedro, Gould, Clare, Birch, Simone, Sehn, Laurie H., Sovani, Vishakha, Ward, Mitchell Steven, Augustson, Bradley, Biccler, Jorne, Connors, Joseph M., Scott, David W., Gandhi, Maher K., Savage, Kerry J., El-Galaly, Tarec, Villa, Diego, and Cheah, Chan Yoon

Published
2019
Full Text
View/download PDF

4. Preoperative breast MR imaging influences surgical management in patients with invasive lobular carcinoma.

Author

Aroney, Stephanie, Lloyd, Thomas, Birch, Simone, Godwin, Belinda, Walters, Kylie, Khoo, Jeremy, Geere, Simone, Shen, Linda, Vujovic, Petar, Bennett, Ian, and Santamaría, Gorane

Subjects
MAGNETIC resonance imaging, BREAST, INTRACLASS correlation, LOBULAR carcinoma, BREAST imaging, MAGNETIC resonance, MAGNETIC resonance mammography
Abstract

Introduction: The purpose of the study is to assess the role of preoperative magnetic resonance (MR) imaging on the surgical management of invasive lobular carcinoma (ILC) and to evaluate whether breast density and background parenchymal enhancement (BPE) influence surgical treatment. Methods: This retrospective study was conducted on 56 patients who were diagnosed with ILC between 2014 and 2020. All patients had mammogram and ultrasound. Preoperative MRI was available in 34 patients. Age, menopausal status, breast density, BPE, multifocality/multicentricity and surgical treatment were collected. Results: Mean pathological tumour size was 36.4 mm (range 5–140 mm). Dense breasts had larger tumours compared to non‐dense breasts (P = 0.072). Of the 34 patients with MRI, 6 opted for mastectomy. Of the remaining 28 cases, MRI findings upgraded surgery to mastectomy in 54% (15/28) because mammogram/ultrasound underestimated tumour extent in 25% (7/28), or multifocal/multicentric disease was identified in 29% (8/28). Tumour size was underestimated by MRI in 7% (2/28). In the non‐MRI subgroup, 64% (14/22) of patients underwent breast‐conserving surgery, but 29% of them (4/14) required a second‐stage mastectomy due to extensive margin involvement. There was no difference in mastectomy rate between patients with MRI (62%) and without MRI (55%) (P = 0.061). Tumour size correlation between MRI and histopathology demonstrated an excellent intraclass correlation coefficient (P < 0.001). Surgical treatment recommendation was not significantly impacted by breast density or BPE. Conclusion: Breast MRI improves surgical management of patients with ILC in providing additional diagnostic information often missed with standard imaging modalities, and without increasing mastectomy rate. Surgical treatment is not impacted by breast density or BPE. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Supplementary Table 1 from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma

Author

Keane, Colm, primary, Gould, Clare, primary, Jones, Kimberley, primary, Hamm, David, primary, Talaulikar, Dipti, primary, Ellis, Jonathan, primary, Vari, Frank, primary, Birch, Simone, primary, Han, Erica, primary, Wood, Peter, primary, Le-Cao, Kim-Anh, primary, Green, Michael R., primary, Crooks, Pauline, primary, Jain, Sanjiv, primary, Tobin, Josh, primary, Steptoe, Raymond J., primary, and Gandhi, Maher K., primary

Published
2023
Full Text
View/download PDF

7. Abstract A17: The immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma

Author

Gunawardana, Jay, primary, Law, Soi C., additional, Sabdia, Muhammed B., additional, Bednarska, Karolina, additional, Brosda, Sandra, additional, Zaharia, Andreea, additional, Tsang, Hennes, additional, de Long, Lilia M., additional, Burgess, Melinda, additional, Talaulikar, Dipti, additional, Lee, Justina N., additional, Jude, Emily, additional, Hawkes, Eliza A., additional, Jain, Sanjiv, additional, Nath, Karthik, additional, Gould, Clare, additional, Swain, Fiona, additional, Tobin, Joshua W. D., additional, Keane, Colm, additional, Birch, Simone, additional, Shanavas, Mohamed, additional, Snell, Cameron, additional, and Gandhi, Maher K., additional

Published
2022
Full Text
View/download PDF

9. Improving outcomes for patients with lymphoma: Design and development of the Australian Lymphoma and Related Diseases Registry

Author

Wood, Erica, primary, Anderson, Mary-Ann, additional, Berkahn, Leanne, additional, Cheah, Chan, additional, Dickinson, Michael, additional, Gandhi, Maher, additional, Giri, Pratyush, additional, Hawkes, Eliza, additional, Johnston, Anna, additional, Keane, Colm, additional, McQuilten, Zoe, additional, Mulligan, Stephen, additional, Talaulikar, Dipti, additional, Opat, Stephen, additional, Trotman, Judith, additional, Williams, Janne, additional, Armytage, Tasman, additional, Barraclough, Allison, additional, Carradice, Duncan, additional, Chong, Geoffrey, additional, Cochrane, Tara, additional, Hamad, Nada, additional, Ku, Matthew, additional, Lee, Denise, additional, Morgan, Susan, additional, Mutsando, Howard, additional, Narayana, Manjunath, additional, Prince, Miles, additional, Ratnasingam, Sumita, additional, Wight, Joel, additional, Badoux, Xavier, additional, Cull, Gavin, additional, Kuss, Byrone, additional, Marlton, Paula, additional, Tam, Constantine, additional, Casan, Joshua, additional, Cushion, Tania, additional, Tedjaseputra, Aditya, additional, Birch, Simone, additional, Brown, Christina, additional, Ellis, David, additional, Harvey, Yasmin, additional, Hitchins, Sam, additional, Jain, Sanjiv, additional, Jessup, Peter, additional, Juneja, Surendar, additional, Kearney, Daniel, additional, Kumar, Beena, additional, Lade, Stephen, additional, Lee, Kenneth, additional, Leslie, Connull, additional, Long, Eileen, additional, Morey, Adrienne, additional, Nath, Lakshmi, additional, Norris, Debra, additional, Parker, Andrew, additional, Parry, Jeremy, additional, Chen, Fiona Pin-Yen, additional, Chung, Eliza, additional, Morison, Jessica, additional, Rowsell, Luke, additional, George, Gayathri St, additional, Thu, Christianto, additional, Waters, Neil, additional, Wellard, Cameron, additional, and Zheng, Michelle, additional

Published
2022
Full Text
View/download PDF

10. The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma

Author

Gunawardana, Jay, primary, Sabdia, Muhammed B., additional, Bednarska, Karolina, additional, Law, Soi C., additional, Brosda, Sandra, additional, Tsang, Hennes, additional, De Long, Lilia Merida, additional, Zaharia, Andreea, additional, Lee, Justina, additional, Jude, Emily, additional, Hawkes, Eliza, additional, Nath, Karthik, additional, Gould, Clare, additional, Burgess, Melinda Lea, additional, Swain, Fiona, additional, Tobin, Joshua W.D., additional, Keane, Colm, additional, Birch, Simone, additional, Talaulikar, Dipti, additional, Jain, Sanjiv, additional, Shanavas, Mohamed, additional, Snell, Cameron, additional, and Gandhi, Maher, additional

Published
2021
Full Text
View/download PDF

11. Abstract A17: The immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma

Author

Jay Gunawardana, Soi Cheng Law, Sabdia, Muhammed B., Karolina Bednarska, Sandra Brosda, Zaharia, Andreea, Hennes Tsang, Lilia Merida de Long, Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Joshua Tobin, colm keane, Birch, Simone, Mohamed Shanavas, Snell, Cameron, and Maher Gandhi

Subjects
General Medicine
Abstract

Hodgkin lymphoma (HL) comprises two distinct disease entities based on clinical, morphologic and genotypic characteristics. Relative to classical Hodgkin Lymphoma (cHL), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is rare, and its tumor microenvironment (TME) is very poorly characterized. With the exception of rituximab, there are no targeted treatments nor advances in the treatment of NLPHL for decades. Unlike cHL, the utility of immune-checkpoint blockade (ICB) has not been evaluated in NLPHL. Diagnostic samples were collected from 49 NLPHL patients from 4 Australian centres and compared with stage-matched cHL patients (and with normal lymph nodes). An integrative transcriptomic, proteomic, T-cell clonal and functional analysis was performed to enable a comparison of the composition of the TME and its contribution to immune-evasion in NLPHL with cHL. 730 cancer-immune related genes were digitally quantified. Relative to cHL, gene set enrichment analysis identified T-cell receptor (TCR) and immune-checkpoint signaling pathway dysregulation in NLPHL. Most striking was prominent differential expression of the immune-transcriptome, particularly enrichment for programmed cell death-1 (PD-1) and T-cell Ig and ITIM domain (TIGIT) in NLPHL versus cHL. These were also over expressed compared to normal lymph nodes. Consistent with this, there was also upregulation of numerous T-cell markers (CD247, CD3D, GZMK, CD28, EOMES) in NLPHL. In contrast, immunosuppressive macrophage (CD163, CD36, CD68, COLEC12, MARCO) and regulatory T-cell genes (FOXP3) were higher in cHL. Importantly, PD-L1 and CD155 (respective ligands for PD-1 and TIGIT) were expressed at the surface of NLPHL and cHL malignant B-cells. Multispectral immunofluorescent microscopy showed intratumoral TIGIT+CD4+ and PD-1+CD4+ T-cells were markedly increased in NLPHL versus cHL and localised within NLPHL follicles. Expanded populations of intratumoral CD4+ T-cell clones were predominantly PD-1+ and frequently also TIGIT+. Multi-parameter flow cytometry and dimensionality reduction was used to establish the distribution of immune checkpoints within circulating T-cell subsets. PD-1+TIGIT+CD4+ T-cells were raised in circulating Treg, TH1 and TH2 subsets in NLPHL versus cHL, and PD-1+TIGIT+ TH2 T-cells displayed raised levels of the exhaustion marker EOMES, collectively indicating systemic T-cell dysfunction. To functionally demonstrate the utility of ICB to stimulate T-cells, an assay using cHL and/or NLPHL cell-lines co-cultured with a genetically engineered effector T-cell-line was developed. This showed that TIGIT/PD-1 dual-blockade was more effective than mono-blockade in inducing NLPHL and cHL tumor-directed CD4+ T-cell activation. Overall, our results indicate that immune-evasion mechanisms in NLPHL are distinct to those operative in cHL, with markedly greater T-cell, PD-1 and TIGIT dysregulation. PD-1 and/or TIGIT blockade warrants evaluation in NLPHL. Citation Format: Jay Gunawardana, Soi C. Law, Muhammed B. Sabdia, Karolina Bednarska, Sandra Brosda, Andreea Zaharia, Hennes Tsang, Lilia M. de Long, Melinda Burgess, Dipti Talaulikar, Justina N. Lee, Emily Jude, Eliza A. Hawkes, Sanjiv Jain, Karthik Nath, Clare Gould, Fiona Swain, Joshua W. D. Tobin, Colm Keane, Simone Birch, Mohamed Shanavas, Cameron Snell, Maher K. Gandhi. The immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma [abstract]. In: Proceedings of the Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; 2022 Jun 23-26; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2022;3(5_Suppl):Abstract nr A17.

Published
2022
Full Text
View/download PDF

16. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy

Author

Zhang, Alison Y., Chiam, Karen, Haupt, Ygal, Fox, Stephen, Birch, Simone, Tilley, Wayne, Butler, Lisa M., Knudsen, Karen, Comstock, Clay, Rasiah, Krishan, Grogan, Judith, Mahon, Kate L., Bianco-Miotto, Tina, Ricciardelli, Carmela, Böhm, Maret, Henshall, Susan, Delprado, Warick, Stricker, Phillip, Horvath, Lisa G., and Kench, James G.

Subjects
Adult, Aged, 80 and over, Male, Prostatectomy, Australia, Prostate, Prostatic Neoplasms, Middle Aged, Prognosis, Article, Cohort Studies, Biomarkers, Tumor, Humans, Neoplasm Metastasis, Neoplasm Recurrence, Local, Aged
Abstract

A plethora of individual candidate biomarkers for predicting biochemical relapse in localized prostate cancer (PCa) have been proposed. Combined biomarkers may improve prognostication, and ensuring validation against more clinically relevant endpoints are required. The Australian PCa Research Centre NSW has contributed to numerous studies of molecular biomarkers associated with biochemical relapse. In the current study, these biomarkers were re-analyzed for biochemical relapse, metastatic relapse and PCa death with extended follow-up. Biomarkers of significance were then used to develop a combined prognostic model for clinical outcomes and validated in a large independent cohort. The discovery cohort (n = 324) was based on 12 biomarkers with a median follow-up of 16 years. Seven biomarkers were significantly associated with biochemical relapse. Three biomarkers were associated with metastases: AZGP1, Ki67 and PML. Only AZGP1 was associated with PCa death. In their individual and combinational forms, AZGP1 and Ki67 as a dual BM signature was the most robust predictor of metastatic relapse (AUC 0.762). The AZPG1 and Ki67 signature was validated in an independent cohort of 347 PCa patients. The dual BM signature of AZGP1 and Ki67 predicted metastasis in the univariable (HR 7.2, 95% CI, 1.6–32; p = 0.01) and multivariable analysis (HR 5.4, 95% CI, 1.2–25; p = 0.03). The dual biomarker signature marginally improved risk prediction compared to AZGP1 alone (AUC 0.758 versus 0.738, p < 0.001). Our findings indicate that biochemical relapse is not an adequate surrogate for metastasis or PCa death. The dual biomarker signature of AZGP1 and Ki67 offers a small benefit in predicting metastasis over AZGP1 alone.

Published
2018

17. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration

Author

Tobin, Joshua W.D., primary, Keane, Colm, additional, Gunawardana, Jay, additional, Mollee, Peter, additional, Birch, Simone, additional, Hoang, Thanh, additional, Lee, Justina, additional, Li, Li, additional, Huang, Li, additional, Murigneux, Valentine, additional, Fink, J. Lynn, additional, Matigian, Nicholas, additional, Vari, Frank, additional, Francis, Santiyagu, additional, Kridel, Robert, additional, Weigert, Oliver, additional, Haebe, Sarah, additional, Jurinovic, Vindi, additional, Klapper, Wolfram, additional, Steidl, Christian, additional, Sehn, Laurie H., additional, Law, Soi-Cheng, additional, Wykes, Michelle N., additional, and Gandhi, Maher K., additional

Published
2019
Full Text
View/download PDF

19. The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma

Author

Keane, Colm, primary, Tobin, Joshua, additional, Gunawardana, Jay, additional, Francis, Santiyagu, additional, Gifford, Grace, additional, Gabrielli, Sara, additional, Gill, Anthony, additional, Stevenson, William, additional, Talaulikar, Dipti, additional, Gould, Clare, additional, Jain, Sanjiv, additional, Birch, Simone, additional, Hertzberg, Mark, additional, and Gandhi, Maher K., additional

Published
2019
Full Text
View/download PDF

20. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy

Author

Zhang, Alison Y., primary, Chiam, Karen, additional, Haupt, Ygal, additional, Fox, Stephen, additional, Birch, Simone, additional, Tilley, Wayne, additional, Butler, Lisa M., additional, Knudsen, Karen, additional, Comstock, Clay, additional, Rasiah, Krishan, additional, Grogan, Judith, additional, Mahon, Kate L., additional, Bianco-Miotto, Tina, additional, Ricciardelli, Carmela, additional, Böhm, Maret, additional, Henshall, Susan, additional, Delprado, Warick, additional, Stricker, Phillip, additional, Horvath, Lisa G., additional, and Kench, James G., additional

Published
2018
Full Text
View/download PDF

21. Elevated LAG-3 Expression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis

Author

Keane, Colm, primary, Law, Soi C, additional, Gould, Clare, additional, Francis, Santiyagu, additional, Abro, Emad Uddin, additional, Tobin, Joshua W.D., additional, Birch, Simone, additional, Gifford, Grace, additional, Gabreilli, Sara, additional, Stevenson, William S., additional, Talaulikar, Dipti, additional, Gill, Anthony, additional, Jain, Sanjiv, additional, Cross, Donna, additional, Hernadez, Annette, additional, Halliday, Sarah-Jane, additional, Bird, Robert, additional, Hertzberg, Mark, additional, and Gandhi, Maher K, additional

Published
2018
Full Text
View/download PDF

22. A Critical Role for Intratumoral and Circulating LAG3 in Classical Hodgkin Lymphoma: Analysis from the Rathl Prospective Phase III International Clinical Trial

Author

Abro, Emad Uddin, primary, Law, Soi C, additional, Keane, Colm, additional, Birch, Simone, additional, Sabdia, Muhammed Bilal, additional, Tobin, Joshua W.D., additional, Johnson, Peter, additional, Trotman, Judith, additional, Berkahn, Leanne, additional, Fulham, Michael, additional, Anderson, Richard A, additional, Saunderson, Anne L, additional, Gunawardana, Jay, additional, Cross, Donna, additional, Hernandez, Annette, additional, Halliday, Sarah-Jane, additional, Bird, Robert, additional, Law, W P, additional, Gill, Devinder, additional, and Gandhi, Maher K, additional

Published
2018
Full Text
View/download PDF

24. An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy.

Author

Zhang, Alison Yan, primary, Chiam, Karen, additional, Haupt, Ygal, additional, Fox, Stephen B., additional, Birch, Simone, additional, Tilley, Wayne, additional, Butler, Lisa, additional, Knudsen, Karen E., additional, Cornstock, Christopher, additional, Rasiah, Krishan, additional, Grogan, Judith, additional, Mahon, Kate Lynette, additional, Bianco-Miotto, Tina, additional, Bohm, Maret, additional, Henshall, Susan M., additional, Delprado, Warick, additional, Stricker, Phillip, additional, Horvath, Lisa, additional, and Kench, James, additional

Published
2018
Full Text
View/download PDF

25. A national pathology review committee for the lymphoma and related diseases registry

Author

Rowsell, Luke, primary, Lade, Stephen, additional, Kumar, Beena, additional, Juneja, Surender, additional, Morey, Adrienne, additional, Jain, Sanjiv, additional, Kearney, Daniel, additional, Ellis, David, additional, Nath, Lakshmi, additional, Jessup, Peter, additional, Young, Eileen, additional, Hitchins, Sam, additional, Lee, Kenneth, additional, Brown, Christina, additional, Leslie, Connull, additional, Parry, Jeremy, additional, Birch, Simone, additional, Norris, Debbie, additional, Harvey, Yasmin, additional, McQuilten, Zoe, additional, Wood, Erica, additional, Opat, Stephen, additional, and Talaulikar, Dipti, additional

Published
2018
Full Text
View/download PDF

26. The Tumor Microenvironment Is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma

Author

Tobin, Joshua W.D., primary, Keane, Colm, additional, Mollee, Peter, additional, Birch, Simone, additional, Gould, Clare, additional, Gunawardana, Jay, additional, Hoang, Thanh, additional, Ma, Ti, additional, Abro, Emad Uddin, additional, Shanavas, Mohamed, additional, Yoo, Hyung, additional, Li, Li, additional, Scuffham, Paul, additional, Murigneux, Valentine, additional, Fink, Lynn, additional, Matigian, Nicholas, additional, Vari, Frank, additional, Francis, Santiyagu, additional, and Gandhi, Maher K, additional

Published
2017
Full Text
View/download PDF

27. The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma

Author

Keane, Colm, primary, Gould, Clare, additional, Jones, Kimberley, additional, Hamm, David, additional, Talaulikar, Dipti, additional, Ellis, Jonathan, additional, Vari, Frank, additional, Birch, Simone, additional, Han, Erica, additional, Wood, Peter, additional, Le-Cao, Kim-Anh, additional, Green, Michael R., additional, Crooks, Pauline, additional, Jain, Sanjiv, additional, Tobin, Josh, additional, Steptoe, Raymond J., additional, and Gandhi, Maher K., additional

Published
2017
Full Text
View/download PDF

29. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

Author

Zhang, Alison Y., Chiam, Karen, Haupt, Ygal, Fox, Stephen, Birch, Simone, Tilley, Wayne, Butler, Lisa M., Knudsen, Karen, Comstock, Clay, Rasiah, Krishan, Grogan, Judith, Mahon, Kate L., Bianco‐Miotto, Tina, Ricciardelli, Carmela, Böhm, Maret, Henshall, Susan, Delprado, Warick, Stricker, Phillip, Horvath, Lisa G., and Kench, James G.

Abstract

A plethora of individual candidate biomarkers for predicting biochemical relapse in localized prostate cancer (PCa) have been proposed. Combined biomarkers may improve prognostication, and ensuring validation against more clinically relevant endpoints are required. The Australian PCa Research Centre NSW has contributed to numerous studies of molecular biomarkers associated with biochemical relapse. In the current study, these biomarkers were re‐analyzed for biochemical relapse, metastatic relapse and PCa death with extended follow‐up. Biomarkers of significance were then used to develop a combined prognostic model for clinical outcomes and validated in a large independent cohort. The discovery cohort (n = 324) was based on 12 biomarkers with a median follow‐up of 16 years. Seven biomarkers were significantly associated with biochemical relapse. Three biomarkers were associated with metastases: AZGP1, Ki67 and PML. Only AZGP1 was associated with PCa death. In their individual and combinational forms, AZGP1 and Ki67 as a dual BM signature was the most robust predictor of metastatic relapse (AUC 0.762). The AZPG1 and Ki67 signature was validated in an independent cohort of 347 PCa patients. The dual BM signature of AZGP1 and Ki67 predicted metastasis in the univariable (HR 7.2, 95% CI, 1.6–32; p = 0.01) and multivariable analysis (HR 5.4, 95% CI, 1.2–25; p = 0.03). The dual biomarker signature marginally improved risk prediction compared to AZGP1 alone (AUC 0.758 versus 0.738, p < 0.001). Our findings indicate that biochemical relapse is not an adequate surrogate for metastasis or PCa death. The dual biomarker signature of AZGP1 and Ki67 offers a small benefit in predicting metastasis over AZGP1 alone. What's new? In prostate cancer survivors, rising PSA levels can presage a return of the tumor. Much research has gone into identifying biomarkers associated with biochemical relapse, but often these biomarkers aren't individually useful for predicting survival. In this study, the authors surveyed a variety of available biomarkers, to test how well they predicted metastatic relapse. While they found seven markers to be associated with biochemical relapse, only two functioned as key predictors of metastasis. The authors propose that biochemical relapse is not a good surrogate for metastasis. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

30. The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)

Author

Keane, Colm, primary, Jones, Kimberly, additional, Gould, Clare, additional, Hamm, David, additional, Wood, Peter, additional, Birch, Simone, additional, Crooks, Pauline, additional, Green, Michael R, additional, Taulaulikar, Dipti, additional, Jain, Sanjiv, additional, Tobin, Josh, additional, and Gandhi, Maher K, additional

Published
2015
Full Text
View/download PDF

41. Endovascular abdominal aortic aneurysm repair: a 7 year experience at the Launceston General Hospital.

Author

Birch SE, Borchard KL, Hewitt PM, Stary D, and Scott AR

Subjects
Aged, Aged, 80 and over, Chi-Square Distribution, Female, Humans, Male, Middle Aged, Postoperative Complications, Statistics, Nonparametric, Treatment Outcome, Aortic Aneurysm, Abdominal surgery, Blood Vessel Prosthesis Implantation methods
Abstract

Background: To review our 7 year experience of endovascular abdominal aortic aneurysm repair (EVR) and to compare this to open repair (OR) during the same time period., Methods: One hundred and one EVR and 65 OR patients were studied. Parameters analysed included patient and procedure details, intensive care unit (ICU) and hospital admission time, and morbidity and mortality with particular emphasis on procedure-related problems., Results: Endovascular grafts were deployed with successful abdominal aortic aneurysm (AAA) exclusion in 100 patients. Primary technical success was achieved in 84%, clinical success in 86% and secondary success in 90% of cases. Complications occurred in 63% and 88% of EVR and OR patients, respectively. Early device-related complications occurred in 40 EVR patients (40%); 24 (60%) were corrected immediately by further stenting. Late device-related complications occurred in 15 EVR patients (15%); four (27%) required additional stenting. Most of the complications in the OR group were systemic (89%) resulting in longer ICU and hospital stays (median 48 vs 17 h and 13 vs 4 days for OR and EVR, respectively). Death within 30 days of the procedure occurred in three EVR patients. There was no perioperative mortality in the OR group., Conclusion: Endovascular AAA repair can be undertaken successfully in a district general hospital. The majority of local and device-related complications can be corrected immediately, while those persisting beyond the initial procedure usually resolve spontaneously. EVR offers a minimally invasive approach to a problem that in the past has involved major surgery.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results